Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [Ga]Ga-DOTA-Siglec-9.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: stage 2 pulmonary sarcoidosis (age 50
I · Intervention 중재 / 시술
[Ga]Ga-DOTA-Siglec-9 PET/CT
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[TRIAL REGISTRATION] ClinicalTrials.gov, NCT03755245 (registered 27 November 2018), NCT05212103 (registered 27 January 2022). [GRAPHICAL ABSTRACT] [Image: see text]
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12931-025-03455-8.
[BACKGROUND] Sarcoidosis is a multisystem granulomatous disease of unknown etiology, with pulmonary involvement being the most common and clinically significant manifestation.
APA
Dadson P, Ylä-Outinen H, et al. (2025). Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [Ga]Ga-DOTA-Siglec-9.. Respiratory research, 27(1). https://doi.org/10.1186/s12931-025-03455-8
MLA
Dadson P, et al.. "Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [Ga]Ga-DOTA-Siglec-9.." Respiratory research, vol. 27, no. 1, 2025.
PMID
41420234 ↗
Abstract 한글 요약
[BACKGROUND] Sarcoidosis is a multisystem granulomatous disease of unknown etiology, with pulmonary involvement being the most common and clinically significant manifestation. Vascular adhesion protein-1 (VAP-1) plays a key role in leukocyte trafficking to inflamed tissues. [⁶⁸Ga]Ga-DOTA-Siglec-9 is a novel PET radiotracer that binds to VAP-1. This proof-of-concept study aimed to evaluate the feasibility of [Ga]Ga-DOTA-Siglec-9 PET/CT for imaging pulmonary sarcoidosis.
[METHODS] Six patients with stage 2 pulmonary sarcoidosis (age 50.5 ± 13.1 years; bodyweight 84.2 ± 14.7 kg), diagnosed by clinical, radiological, and histological findings, underwent [Ga]Ga-DOTA-Siglec-9 PET/CT. Control subjects included six healthy male volunteers (age 37.5 ± 10.3 years; bodyweight 80.3 ± 3.9 kg) and one female patient with lung cancer (age 77 years; bodyweight 62 kg). Tracer uptake was quantified in the lungs, mediastinal lymph nodes, and organs involved in systemic inflammation.
[RESULTS] Patients with sarcoidosis showed significantly higher [Ga]Ga-DOTA-Siglec-9 uptake in the lungs (SUV 1.82 ± 0.52 vs. 0.41 ± 0.08; = 0.00006) and mediastinal lymph nodes (SUV 2.06 ± 0.46 vs. 0.89 ± 0.26; = 0.0003) compared to healthy controls. Increased uptake was also observed in the liver (SUV 1.18 ± 0.14 vs. 0.80 ± 0.10, = 0.0003), spleen (SUV 1.13 ± 0.09 vs. 0.82 ± 0.06, = 0.00003), bone marrow (SUV 0.30 ± 0.12 vs. 0.06 ± 0.05, = 0.001), and bone (SUV 0.27 ± 0.11 vs. 0.08 ± 0.04, 0.004), indicating systemic inflammation.
[CONCLUSIONS] This proof-of-concept study demonstrates the potential of VAP-1-targeted [Ga]Ga-DOTA-Siglec-9 PET/CT for imaging pulmonary sarcoidosis and associated inflammatory activity. Further validation in larger cohorts is warranted.
[TRIAL REGISTRATION] ClinicalTrials.gov, NCT03755245 (registered 27 November 2018), NCT05212103 (registered 27 January 2022).
[GRAPHICAL ABSTRACT] [Image: see text]
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12931-025-03455-8.
[METHODS] Six patients with stage 2 pulmonary sarcoidosis (age 50.5 ± 13.1 years; bodyweight 84.2 ± 14.7 kg), diagnosed by clinical, radiological, and histological findings, underwent [Ga]Ga-DOTA-Siglec-9 PET/CT. Control subjects included six healthy male volunteers (age 37.5 ± 10.3 years; bodyweight 80.3 ± 3.9 kg) and one female patient with lung cancer (age 77 years; bodyweight 62 kg). Tracer uptake was quantified in the lungs, mediastinal lymph nodes, and organs involved in systemic inflammation.
[RESULTS] Patients with sarcoidosis showed significantly higher [Ga]Ga-DOTA-Siglec-9 uptake in the lungs (SUV 1.82 ± 0.52 vs. 0.41 ± 0.08; = 0.00006) and mediastinal lymph nodes (SUV 2.06 ± 0.46 vs. 0.89 ± 0.26; = 0.0003) compared to healthy controls. Increased uptake was also observed in the liver (SUV 1.18 ± 0.14 vs. 0.80 ± 0.10, = 0.0003), spleen (SUV 1.13 ± 0.09 vs. 0.82 ± 0.06, = 0.00003), bone marrow (SUV 0.30 ± 0.12 vs. 0.06 ± 0.05, = 0.001), and bone (SUV 0.27 ± 0.11 vs. 0.08 ± 0.04, 0.004), indicating systemic inflammation.
[CONCLUSIONS] This proof-of-concept study demonstrates the potential of VAP-1-targeted [Ga]Ga-DOTA-Siglec-9 PET/CT for imaging pulmonary sarcoidosis and associated inflammatory activity. Further validation in larger cohorts is warranted.
[TRIAL REGISTRATION] ClinicalTrials.gov, NCT03755245 (registered 27 November 2018), NCT05212103 (registered 27 January 2022).
[GRAPHICAL ABSTRACT] [Image: see text]
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12931-025-03455-8.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.
- Core Needle Biopsies in Patients With Lymphoproliferative Malignancies: An Observational Single-Center Cohort Study.
- Case Report: Application of multimodal imaging in the diagnosis and treatment evaluation of primary cardiac lymphoma.
- Early diagnosis of colorectal cancer using Cerenkov luminescence endoscopy: a pilot trial involving humans for the first time.
- Dynamic fluorine-18 fluorodeoxyglucose PET for evaluating different-sized metastatic lymph nodes in patients with non-small cell lung cancers.